Benefits of combination of insulin degludec and liraglutide are independent of baseline glycated haemoglobin level and duration of type 2 diabetes

AIM: To evaluate, using post hoc analyses, whether the novel combination of a basal insulin, insulin degludec, and a glucagon‐like peptide‐1 receptor agonist, liraglutide (IDegLira), was consistently effective in patients with type 2 diabetes (T2D), regardless of the stage of T2D progression. METHOD...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Diabetes Obes Metab
Main Authors: Rodbard, H. W., Buse, J. B., Woo, V., Vilsbøll, T., Langbakke, I. H., Kvist, K., Gough, S. C. L.
Formato: Artigo
Idioma:Inglês
Publicado em: Blackwell Publishing Ltd 2016
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5063148/
https://ncbi.nlm.nih.gov/pubmed/26343931
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.12574
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados